Stem cell transplant offers new hope for kids with rare immune diseases
NCT ID NCT01652092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system. The study tracks how well the new cells take hold and if there are any complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
57 people
The number who actually took part.
- Started
-
Sep 2012
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of immunodeficiency or histiocytic disorder including the following: * Severe combined immunodeficiency (SCID - all variants) * Second bone marrow transplant (BMT) for SCID (after graft rejection) * Omenn's Syndrome * Reticular dysgenesis * Wiskott-Aldrich syndrome * Major histocompatibility complex (MHC) Class II deficiency (bare lymphocyte syndrome) * Hyper IgM Syndrome (CD40 Ligand Deficiency) * Common variable immunodeficiency (CVID) with severe phenotype * Chronic Granulomatous Disease (CGD) * Other severe Combined Immune Deficiencies (CID) * Hemophagocytic Lymphohistiocytosis (HLH) * X-linked Lymphoproliferative Disease (XLP) * Chediak-Higashi Syndrome (CHS) * Griscelli Syndrome * Langerhans Cell Histiocytosis (LCH) * Acceptable stem cell sources include: * HLA identical or 1 antigen matched sibling donor eligible to donate bone marrow * HLA identical or up to a 1 antigen mismatched unrelated BM donor * Sibling donor cord blood with acceptable HLA match and cell dose as per current institutional standards * Single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum cell dose of \>5 x 10\^7 nucleated cells/kg as per current institutional guidelines * Double unrelated umbilical cord blood units that are: * up to 2 antigen mismatched to the patient * up to 2 antigen mismatched to each other * minimum cell dose of at least one single unit must be ≥ 3.5 x 10\^7 nucleated cells/kg * combined dose of both units must provide a total cell dose of ≥ 5 x 10\^7 nucleated cells/kg * Age: 0 to 50 years * Adequate organ function and performance status. Exclusion Criteria * pregnant or breastfeeding * active, uncontrolled infection and/or HIV positive * acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bare lymphocyte syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
- Can a new antibody make stem cell transplants safer for CGD patients?
- A 5-Day genetic test could slash time to transplant for children with rare immune disease
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Newborn screening study aims to catch rare diseases at birth